Is 11C-choline the most appropriate tracer for prostate cancer?: For

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 31, Issue 5, 2004, Pages 753-755

  Fazio, Ferruccio ^a   Picchio, Maria ^a   Messa, Cristina ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; CHOLINE; FLUORODEOXYGLUCOSE F 18; TRACER; CARBON; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

CANCER SCINTISCANNING; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; HUMAN; IMAGING SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; SHORT SURVEY; WHOLE BODY SCINTISCANNING; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; EVALUATION; EVIDENCE BASED MEDICINE; MALE; METHODOLOGY; PROSTATE TUMOR; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

CARBON RADIOISOTOPES; CHOLINE; CLINICAL TRIALS; EVIDENCE-BASED MEDICINE; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 2442530572     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-004-1542-9     Document Type: Short Survey

References (31)

1. Gittes RF. Carcinoma of the prostate. N Engl J Med 1991; 324:236-245.
2. Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol 2000; 163:1632-1642.
3. Hoh CK, Schiepers C, Seltzer MA, Gambhir SS, Silverman DH, J. Czernin J, Maddahi J, Phelps ME. PET in oncology: will it replace the other modalities? Semin Nucl Med 1997; 27:94-106.
4. Rosenthal DI. Radiologic diagnosis of bone metastases. Cancer 1997; 80 (Suppl): 1595-1607.
5. Hricak H, Schoder H, Pucar D, Lis E, Eberhardt SC, Onyebuchi CN, Scher HI. Advances in imaging in the postoperative patient with a rising prostate-specific antigen level. Semin Oncol 2003; 30:616-634.
6. Silverman JM, Krebs TL. MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. AJR Am J Roentgenol 1997; 168:379-385.
7. 11C]choline. J Nucl Med 1997; 38:842-847.
8. 11C]choline; implications for in vivo imaging withositron emission tomography. Eur J Nucl Med 2000; 27:25-32.
9. 18F]fluoro-D-glucose in tumor imaging with positron emission tomography. Mol Imaging Biol 2002; 4:267-273.
10. Kotzerke J, Prang J, Neumaier B, Volkmer B, Guhlmann A, Kleinschmidt K, Hautmann R, Reske SN. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 2000; 27:1415-1419.
11. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998; 39:990-995.
12. 11C]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging 2003; 31:317-324.
13. 11C-choline positron emission tomography. Eur Urol 2002; 42:18-23.
14. 11C-choline PET. J Nucl Med 2003; 44:331-335.
15. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003; 44:32-38.
16. 18F]fluorodeoxyglucose-positron emission tomography. J Urol 2003; 169:1337-1340.
17. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998; 39:990-995.
18. 18F]FDG with positron emission tomography in recurrence of prostate cancer. AJR Am J Roentgenol 2002; 179:482-484.
19. 18F]fluoro-2-deoxy-D-glucose in oncology. Part II. The clinical value in detecting and staging primary tumours. J Cancer Res Clin Oncol 2000; 126: 560-574.
20. Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999; 36:31-35.
21. Thomas CT, Bradshaw PT, Pollock BH, Montie JE, Taylor JM, Thames HD, McLaughlin PW, DeBiose DA, Hussey DH, Wahl RL. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol 2003; 21:1715-1721.
22. 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 2003; 30:607-611.
23. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 2003; 44:556-558.
24. 11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. Eur J Nucl Med Mol Imaging 2002; 29:1492-1495.
25. 11C-acetate PET imaging of prostate cancer. J Nucl Med 2002; 43:181-186.
26. 11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 2003; 42:25-30.
27. 11C-acetate. J Nucl Med 2003; 44:549-555.
28. Wawroschek F, Wengenmair H, Senekowitsch-Schmidtke R, Hamm M, Henke J, Schonberger T, Hauser A, Erhardt W, Harzmann R. Prostate lymphoscintigraphy and radioguided surgery for sentinel lymph node identification in prostate cancer. Technique and results of the first 350 cases. Urol Int 2003; 70:303-310.
29. Coleman R, DeGrado T, Wang S, Baldwin S, Orr M, Reiman R, Price D. Preliminary evaluation of F-18 fluorocholine (FCH) as a PET tumor imaging agent. Clin Positron Imaging 2000; 3:147.
30. DeGrado TR, Baldwin SW, Wang S, Orr MD, Liao RP, Friedman HS, Reiman R, Price DT, Coleman RE. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001; 42:1805-1814.
31. Pelosi E, Messa C, Sironi S, Picchio M, Landoni C, Bettinardi V, Gianolli L, Del Maschio A, Gilardi MC, Fazio F. Value of integrated PET/CT for lesion localization in cancer patients: a comparative study. Eur J Nucl Med Mol Imaging 2004; 31:in press. DOI 10.1007/s00259-004-1483-3.